Skip to main content

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties Hepatobiliars (GRC)

IP: Malalties Hepatobiliars (GRC)
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Malalties Hepatobiliars (GRC), Silvia Sauleda Oliveras, Malalties Hepatobiliars (GRC), Maria Buti Ferret, Malalties Hepatobiliars (GRC), Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Análisis de situación y estrategia de manejo de pacientes con infección crónica por VHB sin criterios de tratamiento según las guías de la Asociación Europea para el estudio del hígado

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 39591
Reference: GLD13/00137
Duration: 18/09/2013 - 17/09/2014

Prevalencia de las quasispecies mutantes en antígeno de superficie en paceintes con hepatitis crónica B y trasplantados por hepatitis B

IP: Maria Buti Ferret
Collaborators: Andrea Caballero Garralda, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 275715.44
Reference: PI11/01973
Duration: 01/01/2012 - 28/02/2015

Análisis de la cuasispecie viral en la infección por virus de la hepatitis B: evolución natural yu asociada al tratamiento antiviral

IP: -
Collaborators: Maria Buti Ferret, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI09/00899
Duration: 01/01/2010 - 31/12/2012

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Irene  Torrecilla Martinez

Irene Torrecilla Martinez

Epidemiology and Public Health
Read more
Jorge Pérez López

Jorge Pérez López

Genetics Medicine
Read more
Genoveva Arqueros Sánchez

Genoveva Arqueros Sánchez

Tècnic/a Grau Superior
Labour Relations Unit
Human Resources Directorate
Read more
Mª Eulàlia Joseph Munné

Mª Eulàlia Joseph Munné

Medium Grade Technician
General Services and Infrastructures Unit
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.